Previous close | 0.1600 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.1500 |
Strike | 5.00 |
Expiry date | 2024-09-20 |
Day's range | 0.1600 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 73 |
Explore PAVmed Inc's strategic initiatives and financial performance, including a significant partnership with Ohio State's James Cancer Hospital and a robust Series B financing round.
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024.